Articles

Bioinformatics: the next big thing in life sciences

20th August 2014

Bioinformatics: the next big thing in life sciencesWill Spooner

Bioinformatics is starting to show its strength as a tool to interpret and analyse vast amounts of complex data in the search for new drugs.While the field of bioinformatics has... Read more

The future of the UK pharma market: Part One: the global context

19th August 2014

The future of the UK pharma market:  Part One: the global contextSarah Rickwood

The UK's reputation as a problematic, slow uptake market doesn't capture the whole picture – it is a pioneer in many respects, and still a key market for new product... Read more

The mobile moonshot

18th August 2014

The mobile moonshotFabio Gratton

Though mobile phone apps have long been regarded as potential 'game changers' in healthcare, the journey has been slower than many digital gurus expected, with surprisingly few apps actually designed... Read more

Pharma Gets Social: How Johnson & Johnson engages nurses in rich i…

15th August 2014

Pharma Gets Social: How Johnson & Johnson engages nurses in rich integrated digital campaignDaniel Ghinn

This month, Daniel Ghinn examines how Johnson & Johnson's integrated social media channels are working to support nurses and prospective nurses.By 2020, the US will face a shortage of 800,000... Read more

News

Novartis invests in novel stem cell technology

20th August 2014

Novartis invests in novel stem cell technologyLinda Banks

Novartis is to invest $35 million in Israeli company Gamida Cell, to develop novel stem cell treatment NiCord for blood cancers such as leukaemia and lymphoma. In return, Novartis will... Read more

NICE yes for Revlimid after price limit

20th August 2014

NICE yes for Revlimid after price limitAndrew McConaghie

NICE has recommended Celgene's Revlimid (lenalidomide) as an option for treating myelodysplastic syndromes.The institute has reversed its opinion of the drug in its final draft guidance after Celgene provided further evidence to... Read more

Eisai files Fycompa for wider epilepsy use

20th August 2014

Eisai files Fycompa for wider epilepsy useAndrew McConaghie

Eisai is looking to extend the use of its epilepsy treatment Fycompa into use as adjunctive treatment of serious seizures uncontrolled by existing treatment.Eisai has just submitted the drug to the EMA for... Read more

Diabetes drug Basaglar receives tentative FDA approval

19th August 2014

Diabetes drug Basaglar receives tentative FDA approvalLinda Banks

The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boehringer Ingelheim's (BI) diabetes alliance, following litigation filed by Sanofi claiming patent infringement.The terms... Read more

Audio & Video

Patient Opinion Leaders: Andrew Schorr

 

As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

View the recorded webinar - The future o…

WEBINAR COVER smaller


The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health... View more

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

White Papers

Diabetes in France

Diabetes in FranceJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Diabetes in Germany

Diabetes in GermanyJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Connected data and the use of smartphone…

Connected data and the use of smartphone enabled apps in market researchPaul Mannu

Rapid growth in smartphone usage offers healthcare researchers a useful tool to gain better understanding of how patients and healthcare professionals actually behave on a daily basis. Inaccuracies can arise... View info

Diabetes in the UK

Diabetes in the UKJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Further News & Articles

Bioscience would lose out in an independent Scotland, warns minister

A UK government science minister has warned that Scotland's life sciences sector would lose out if the country d... Read more

News

Eisai ‘outraged’ by decision on epilepsy drug

A ruling in Germany which has found Eisai's epilepsy drug Fycompa to have no extra benefits to existing treat... Read more

News

NICE to re-evaluate Firmagon for advanced hormone-dependent prostate cancer

A successful appeal against NICE's decision on prostate cancer drug Firmagon (degarelix) means the UK's cost-eff... Read more

News

NICE failure to agree a Zytiga price with Janssen is 'fiasco'

Medical charity Prostate Cancer UK has reacted angrily to the news that NICE has rejected Janssen's Zytiga for b... Read more

News

NICE says yes to Sovaldi – but some patients will miss out

New Hepatitis C treatment Sovaldi has been approved by NICE in a broad range of patients, despite concerns about... Read more

News

FDA approves Avastin for aggressive and late-stage cervical cancer

The US Food and Drug Administration (FDA) has approved a new use for Roche's Avastin (bevacizumab) to treat pati... Read more

News